ArticleMolecular and cellular biology1997
Reconstitution of a MEC1-independent checkpoint in yeast by expression of a novel human fork head cDNA.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.Cancer discovery · 2014Pooled it
- The clinical and prognostic significance of FOXN3 downregulation in acute myeloid leukaemia.International journal of laboratory hematology · 2020Trial
- Foxn3 is part of a transcriptional network that regulates primary cilia in the developing retina.Development (Cambridge, England) · 2026Article
- FOXN3 integrates the KU70/KU80/SREBP-1 complex to regulate lipid metabolism in non-alcoholic fatty liver disease.Nucleic acids research · 2026Article
- Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer.Cell death discovery · 2022Article
- Bioinformatic analysis of FOXN3 expression and prognostic value in pancreatic cancer.Frontiers in oncology · 2022Article
- Nuclear TARBP2 Drives Oncogenic Dysregulation of RNA Splicing and Decay.Molecular cell · 2019Article
- Novel tumor-suppressor FOXN3 is downregulated in adult acute myeloid leukemia.Oncology letters · 2019Article
- Bispecific Forkhead Transcription Factor FoxN3 Recognizes Two Distinct Motifs with Different DNA Shapes.Molecular cell · 2019Article
- Recent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies.Frontiers in oncology · 2019Review
- Checkpoint suppressor 1 suppresses transcriptional activity of ERα and breast cancer cell proliferation via deacetylase SIRT1.Cell death & disease · 2018Article
- The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer.The Journal of clinical investigation · 2017Article
- The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.Oncotarget · 2016Article
- FOXN3 Regulates Hepatic Glucose Utilization.Cell reports · 2016Article
- CHES1/FOXN3 regulates cell proliferation by repressing PIM2 and protein biosynthesis.Molecular biology of the cell · 2014Article
- Article
- Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2013Article
- Cranial muscles in amphibians: development, novelties and the role of cranial neural crest cells.Journal of anatomy · 2013Review
- Follow-up association study of linkage regions reveals multiple candidate genes for carotid plaque in Dominicans.Atherosclerosis · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
A novel human cDNA, CHES1 (checkpoint suppressor 1), has been isolated by suppression of the mec1-1 checkpoint mutation in Saccharomyces cerevisiae. CHES1 suppresses a number of DNA damage-activated checkpoint mutations in S. cerevisiae, including mec1, rad9, rad24, dun1, and rad53. CHES1 suppression of sensitivity to DNA damage is specific for checkpoint-defective strains, in contrast to DNA repair-defective strains. Presence of CHES1 but not a control vector resulted in G2 delay after UV irradiation in checkpoint-defective strains, with kinetics, nuclear morphology, and cycloheximide resistance similar to those of a wild-type strain. CHES1 can also suppress the lethality, UV sensitivity, and G2 checkpoint defect of a mec1 null mutation. In contrast to this activity, CHES1 had no measurable effect on the replication checkpoint as assayed by hydroxyurea sensitivity of a mec1 strain. Sequence analysis demonstrates that CHES1 is a novel member of the fork head/Winged Helix family of transcription factors. Suppression of the checkpoint-defective phenotype requires a 200-amino-acid domain in the carboxy terminus of the protein which is distinct from the DNA binding site. Analysis of CHES1 activity is most consistent with activation of an alternative MEC1-independent checkpoint pathway in budding yeast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.